An illustration · invented records · this source is real
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial
Sparano JA, Gray RJ, Makower DF, Albain KS, et al. (2020). JAMA Oncology. PubMed 31566680 · DOI 10.1001/jamaoncol.2019.4794 · PubMed record
What kind of source: Secondary analysis of TAILORx, high-score group. Where it sits in the summary: Still being studied. Back to the summary
What it says, in plain language
What happened to the women with high scores, who all received chemotherapy. Outcomes were better than expected for that risk group, which supports but does not prove that chemotherapy helped them.
Source access: this note uses the published abstract, linked above. The full article was not available for this review and is not included in the folder.
The exact words we relied on
“At 5 years, the estimated rate of freedom from recurrence of breast cancer at a distant site was 93.0% (standard error [SE], 0.8%)” — PMID:31566680, Abstract, Results
“an outcome better than expected with endocrine therapy alone in this population.” — PMID:31566680, Abstract, Conclusions and Relevance
How these quotes were checked
Follow the passage links above to the included paper or public source record.
Abstract only. The quotes above come from the paper’s published abstract as held in the PubMed record. They were checked by exact string match against the PubMed record cached on 2026-09-08. This note is limited to the abstract; the full article was not read.
Limits of this source
No comparison group: these women were not randomized, so the benefit of chemotherapy at high scores is inferred from expected outcomes, not measured directly in this trial. Abstract only.
Review
Reviewed by Sarah Kiselycznyk · September 10, 2026. Review scope and verification method: How we researched this.